PT2654790T - Anticorpo modificado com semivida melhorada - Google Patents
Anticorpo modificado com semivida melhoradaInfo
- Publication number
- PT2654790T PT2654790T PT11850362T PT11850362T PT2654790T PT 2654790 T PT2654790 T PT 2654790T PT 11850362 T PT11850362 T PT 11850362T PT 11850362 T PT11850362 T PT 11850362T PT 2654790 T PT2654790 T PT 2654790T
- Authority
- PT
- Portugal
- Prior art keywords
- life
- modified antibody
- improved half
- improved
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Plant Pathology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Physics & Mathematics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061425858P | 2010-12-22 | 2010-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2654790T true PT2654790T (pt) | 2019-05-16 |
Family
ID=46312907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT11850362T PT2654790T (pt) | 2010-12-22 | 2011-12-22 | Anticorpo modificado com semivida melhorada |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9505826B2 (enExample) |
| EP (1) | EP2654790B1 (enExample) |
| JP (2) | JP6147670B2 (enExample) |
| KR (1) | KR101941514B1 (enExample) |
| CN (1) | CN103429261A (enExample) |
| AU (1) | AU2011349049B2 (enExample) |
| BR (1) | BR112013016235B1 (enExample) |
| CA (1) | CA2824279A1 (enExample) |
| EA (1) | EA201390923A1 (enExample) |
| ES (1) | ES2720136T3 (enExample) |
| IL (1) | IL227081B (enExample) |
| MX (1) | MX2013007392A (enExample) |
| PT (1) | PT2654790T (enExample) |
| WO (1) | WO2012083370A1 (enExample) |
| ZA (1) | ZA201305123B (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2654790B1 (en) * | 2010-12-22 | 2019-02-06 | Teva Pharmaceuticals Australia Pty Ltd | Modified antibody with improved half-life |
| EA034989B1 (ru) | 2011-10-28 | 2020-04-15 | Тева Фармасьютикал Австралия Пти Лтд | Полипептидная конструкция для применения при лечении рака, включающая аттенуированный альфа-интерферон |
| EP4613778A3 (en) | 2012-10-25 | 2025-12-17 | Bioverativ USA Inc. | Anti-complement c1s antibodies and uses thereof |
| PL2914291T3 (pl) | 2012-11-02 | 2022-10-03 | Bioverativ Usa Inc. | Przeciwciała anty-C1s dopełniacza i ich zastosowania |
| EP4116331A1 (en) | 2012-12-17 | 2023-01-11 | PF Argentum IP Holdings LLC | Treatment of cd47+ disease cells with sirp alpha-fc fusions |
| ITTO20130012A1 (it) | 2013-01-09 | 2014-07-10 | Metheresis Translational Res S A | Nuovi frammenti anticorpali, relative composizioni ed usi |
| US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
| CA2904805A1 (en) | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
| AU2014261630B2 (en) | 2013-04-29 | 2019-05-09 | F. Hoffmann-La Roche Ag | Human FcRn-binding modified antibodies and methods of use |
| UA113129C2 (xx) | 2013-04-29 | 2016-12-12 | ЗЛИТА КОНСТРУКЦІЯ АНТИТІЛО ПРОТИ CD38 З ОСЛАБЛЕНИМ ІНТЕРФЕРОНОМ АЛЬФА-2b | |
| KR101895634B1 (ko) * | 2013-05-31 | 2018-09-05 | 한미약품 주식회사 | 변이된 힌지 영역을 포함하는 IgG4 Fc 단편 |
| MX377002B (es) * | 2013-07-05 | 2025-03-07 | H Lee Moffitt Cancer Ct & Res | Cd33 soluble para tratar síndromes mielodisplásicos (mds). |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| CN105916880B (zh) | 2014-01-15 | 2020-01-17 | 豪夫迈·罗氏有限公司 | 具有改善的蛋白A结合作用的Fc区变体 |
| UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
| KR102130600B1 (ko) | 2014-07-03 | 2020-07-08 | 베이진 엘티디 | Pd-l1 항체와 이를 이용한 치료 및 진단 |
| MY184890A (en) | 2014-07-10 | 2021-04-29 | Bioarctic Neuroscience Ab | Improved a? protofibril binding antibodies |
| CA2959629C (en) | 2014-09-03 | 2023-10-31 | Boehringer Ingelheim International Gmbh | Compound targeting il-23a and tnf-alpha and uses thereof |
| IL251822B2 (en) | 2014-10-29 | 2023-03-01 | Teva Pharmaceuticals Australia Pty Ltd | Variants of interferon alpha-2-b |
| US20160130324A1 (en) * | 2014-10-31 | 2016-05-12 | Shire Human Genetic Therapies, Inc. | C1 Inhibitor Fusion Proteins and Uses Thereof |
| KR102654033B1 (ko) * | 2014-12-08 | 2024-04-02 | 1글로브 바이오메디칼 씨오., 엘티디. | 가용성 유니버셜 adcc 증강 합성 융합 유전자 및 펩티드 기술 및 그 용도 |
| EP3303386B1 (en) | 2015-06-05 | 2024-08-28 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| US20160362473A1 (en) * | 2015-06-12 | 2016-12-15 | Ubi Pharma Inc | Immunoglobulin fusion proteins and uses thereof |
| US11820807B2 (en) * | 2015-06-12 | 2023-11-21 | Ubi Pharma Inc | Immunoglobulin fusion proteins and uses thereof |
| AU2016274890B2 (en) * | 2015-06-12 | 2022-02-10 | Ubi Pharma Inc | Immunoglobulin fusion proteins and uses thereof |
| SG10201912593VA (en) | 2015-07-23 | 2020-02-27 | Boehringer Ingelheim Int | Compound targeting il-23a and b-cell activating factor (baff) and uses thereof |
| EP3222672A1 (de) * | 2016-03-23 | 2017-09-27 | LANXESS Deutschland GmbH | Metallazopigmente |
| CN109475536B (zh) | 2016-07-05 | 2022-05-27 | 百济神州有限公司 | 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合 |
| TWI750194B (zh) * | 2016-07-05 | 2021-12-21 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ｅｇｆｒ抗體-藥物偶聯物及其在醫藥上的應用 |
| AU2017325654B2 (en) | 2016-08-02 | 2024-09-05 | Visterra, Inc. | Engineered polypeptides and uses thereof |
| FI3500299T3 (fi) | 2016-08-19 | 2024-02-14 | Beigene Switzerland Gmbh | Tsanubrutinibin yhdistelmä cd20-tai pd-1-vasta-aineen kanssa käytettäväksi syövän hoidossa |
| US20200048332A1 (en) | 2016-10-12 | 2020-02-13 | Bioverativ Usa Inc. | Anti-c1s antibodies and methods of use thereof |
| CA3042581A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Enhancement of cd47 blockade therapy by proteasome inhibitors |
| JP2020511937A (ja) | 2016-12-07 | 2020-04-23 | ジェネンテック， インコーポレイテッド | 抗ｔａｕ抗体及び使用方法 |
| TW202328181A (zh) | 2016-12-07 | 2023-07-16 | 美商建南德克公司 | 抗-tau抗體及使用方法 |
| EP3573989A4 (en) | 2017-01-25 | 2020-11-18 | Beigene, Ltd. | CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES |
| CA3064522A1 (en) * | 2017-05-26 | 2018-11-29 | Glaxosmithkline Intellectual Property Development Limited | Biopharmaceutical compositions and related methods |
| US11597768B2 (en) | 2017-06-26 | 2023-03-07 | Beigene, Ltd. | Immunotherapy for hepatocellular carcinoma |
| TWI801425B (zh) | 2017-09-29 | 2023-05-11 | 大陸商江蘇恆瑞醫藥股份有限公司 | Il-5 抗體、其抗原結合片段及醫藥用途 |
| US11786529B2 (en) | 2017-11-29 | 2023-10-17 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors |
| CN109942706A (zh) * | 2017-12-21 | 2019-06-28 | 三生国健药业（上海）股份有限公司 | 结合人il-5的单克隆抗体、其制备方法和用途 |
| CN113227134A (zh) | 2018-12-05 | 2021-08-06 | 株式会社梅花治疗 | 抗体的Fc区变体 |
| CN110297093B (zh) * | 2019-03-18 | 2022-04-22 | 山西瑞豪生物科技有限公司 | 一种检测人免疫球蛋白g4的方法和试剂盒 |
| MX2021011530A (es) | 2019-03-29 | 2021-10-22 | Jiangsu Hengrui Medicine Co | Composicion farmaceutica que contiene anticuerpos contra il-5 y su uso. |
| WO2021138407A2 (en) * | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
| US20230057939A1 (en) | 2020-01-13 | 2023-02-23 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of il-7 protein and a bispecific antibody |
| CN113307870B (zh) * | 2020-10-30 | 2022-12-23 | 上海洛启生物医药技术有限公司 | 抗il5纳米抗体及其应用 |
| KR20220068144A (ko) * | 2020-11-18 | 2022-05-25 | 주식회사 녹십자 | 자가 항체에 대한 회피율 또는 활성이 증가된 adamts13 변이체 |
| CA3199589A1 (en) * | 2020-11-19 | 2022-05-27 | Ping Li | Long-acting nerve growth factor polypeptides and uses thereof |
| TW202322850A (zh) * | 2021-08-05 | 2023-06-16 | 美商美國禮來大藥廠 | 抗體最佳化 |
| CN120077065A (zh) | 2022-07-27 | 2025-05-30 | 阿布林克斯有限公司 | 与新生儿Fc受体的特定表位结合的多肽 |
| JPWO2024048683A1 (enExample) | 2022-08-30 | 2024-03-07 | ||
| KR20240072322A (ko) * | 2022-11-10 | 2024-05-24 | (주)네오크레마 | Il-22를 포함하는 융합 단백질 및 이의 용도 |
| EP4658310A1 (en) | 2023-01-30 | 2025-12-10 | Kymab Limited | Antibodies |
| TW202448926A (zh) | 2023-02-17 | 2024-12-16 | 比利時商艾伯霖克斯公司 | 結合新生兒fc受體之多肽 |
| CN120189527A (zh) * | 2025-05-27 | 2025-06-24 | 南方医科大学第三附属医院（广东省骨科研究院） | 一种多肽与抗体Fc片段的偶联物、药物组合物及其用途 |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| ATE151110T1 (de) | 1988-09-02 | 1997-04-15 | Protein Eng Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| IT1237881B (it) | 1989-12-12 | 1993-06-18 | Fast Spa | Struttura a profilo complesso, applicabile su apparecchi agitatori, per il bloccaggio di barattoli di vernice, aventi coperchi comunque diversificati |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| CA2050918A1 (en) | 1990-01-12 | 1991-07-13 | Raju Kucherlapati | Generation of xenogeneic antibodies |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| EP0564531B1 (en) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| DK1471142T3 (da) | 1991-04-10 | 2009-03-09 | Scripps Research Inst | Heterodimere receptor-biblioteker under anvendelse af fagemider |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| WO1992022324A1 (en) | 1991-06-14 | 1992-12-23 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| IL104620A (en) * | 1992-02-06 | 2000-02-29 | Schering Plough Corp | Humanized monoclonal antibodies against human interleukin-5 |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| WO1994011026A2 (en) | 1992-11-13 | 1994-05-26 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
| WO1994012520A1 (en) | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Linker for linked fusion polypeptides |
| US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
| WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
| EP1231268B1 (en) | 1994-01-31 | 2005-07-27 | Trustees Of Boston University | Polyclonal antibody libraries |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| GB9412230D0 (en) * | 1994-06-17 | 1994-08-10 | Celltech Ltd | Interleukin-5 specific recombiant antibodies |
| USRE39548E1 (en) | 1994-06-17 | 2007-04-03 | Celltech R&D Limited | Interleukin-5 specific recombinant antibodies |
| US6056957A (en) | 1994-08-04 | 2000-05-02 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-5 |
| US5783184A (en) | 1994-12-23 | 1998-07-21 | Smithkline Beecham Corporation | Method for treatment and diagnosis of IL-5 mediated disorders |
| DK0800536T3 (da) | 1994-12-23 | 2007-04-02 | Smithkline Beecham Corp | Rekombinante IL-5 antagonister, der er nyttige til behandling af IL-5-medierede lidelser |
| US5683892A (en) | 1994-12-23 | 1997-11-04 | Smithkline Beecham Corporation | DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
| US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US5747035A (en) | 1995-04-14 | 1998-05-05 | Genentech, Inc. | Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| WO1997043316A1 (en) | 1996-05-10 | 1997-11-20 | Beth Israel Deaconess Medical Center, Inc. | Physiologically active molecules with extended half-lives and methods of using same |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| DK1500329T3 (da) | 1996-12-03 | 2012-07-09 | Amgen Fremont Inc | Humane antistoffer, der specifikt binder TNF-alfa |
| WO1998046645A2 (en) | 1997-04-14 | 1998-10-22 | Micromet Gesellschaft Für Biomedizinische Forschung Mbh | Method for the production of antihuman antigen receptors and uses thereof |
| DE69833755T2 (de) | 1997-05-21 | 2006-12-28 | Biovation Ltd. | Verfahren zur herstellung von nicht-immunogenen proteinen |
| PL199659B1 (pl) | 1998-02-25 | 2008-10-31 | Merck Patent Gmbh | Białko fuzyjne przeciwciała hu-KS IL2, cząsteczka DNA kodująca białko fuzyjne przeciwciała hu-KS IL2 i sposób wytwarzania białka fuzyjnego przeciwciała hu-KS IL2 |
| EP1051432B1 (en) | 1998-12-08 | 2007-01-24 | Biovation Limited | Method for reducing immunogenicity of proteins |
| AU2002248184C1 (en) * | 2000-12-12 | 2018-01-04 | Board Of Regents, The University Of Texas System | Molecules with extended half-lives, compositions and uses thereof |
| US8178098B2 (en) | 2001-04-03 | 2012-05-15 | National Jewish Health | Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies |
| EP2298809A3 (en) | 2001-07-12 | 2012-02-15 | FOOTE, Jefferson | Super humanized antibodies |
| AU2003217912A1 (en) * | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| CA2479927C (en) * | 2002-03-29 | 2013-03-12 | Schering Corporation | Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same |
| US20070135620A1 (en) | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| TWI461436B (zh) * | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法 |
| GB0612928D0 (en) * | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
| WO2008134046A1 (en) * | 2007-04-27 | 2008-11-06 | Genentech, Inc. | Potent, stable and non-immunosuppressive anti-cd4 antibodies |
| US8092804B2 (en) * | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| EP2250279B1 (en) * | 2008-02-08 | 2016-04-13 | MedImmune, LLC | Anti-ifnar1 antibodies with reduced fc ligand affinity |
| EP3482769B1 (en) | 2008-12-19 | 2024-05-29 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| BRPI1006998A2 (pt) | 2009-01-23 | 2015-08-25 | Biogen Idec Inc | Polipeptídeos fc estabilizados com função efetora reduzida e métodos de uso |
| CA2749200A1 (en) * | 2009-01-29 | 2010-08-05 | Michael Bowen | Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases |
| MX2011011728A (es) | 2009-05-04 | 2012-04-19 | Abbott Res Bv | Anticuerpos contra el factor de crecimiento nervioso (ngf) con estabilidad in vivo mejorada. |
| EP2654790B1 (en) * | 2010-12-22 | 2019-02-06 | Teva Pharmaceuticals Australia Pty Ltd | Modified antibody with improved half-life |
-
2011
- 2011-12-22 EP EP11850362.2A patent/EP2654790B1/en active Active
- 2011-12-22 PT PT11850362T patent/PT2654790T/pt unknown
- 2011-12-22 KR KR1020137019148A patent/KR101941514B1/ko active Active
- 2011-12-22 WO PCT/AU2011/001662 patent/WO2012083370A1/en not_active Ceased
- 2011-12-22 EA EA201390923A patent/EA201390923A1/ru unknown
- 2011-12-22 MX MX2013007392A patent/MX2013007392A/es unknown
- 2011-12-22 CA CA2824279A patent/CA2824279A1/en not_active Abandoned
- 2011-12-22 JP JP2013544971A patent/JP6147670B2/ja active Active
- 2011-12-22 US US13/996,733 patent/US9505826B2/en active Active
- 2011-12-22 BR BR112013016235-0A patent/BR112013016235B1/pt active IP Right Grant
- 2011-12-22 CN CN201180068272XA patent/CN103429261A/zh active Pending
- 2011-12-22 ES ES11850362T patent/ES2720136T3/es active Active
- 2011-12-22 AU AU2011349049A patent/AU2011349049B2/en active Active
-
2013
- 2013-06-20 IL IL227081A patent/IL227081B/en active IP Right Grant
- 2013-07-08 ZA ZA2013/05123A patent/ZA201305123B/en unknown
-
2016
- 2016-12-28 JP JP2016255652A patent/JP6334669B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012083370A1 (en) | 2012-06-28 |
| CN103429261A (zh) | 2013-12-04 |
| EP2654790A4 (en) | 2014-05-28 |
| JP6334669B2 (ja) | 2018-05-30 |
| ES2720136T3 (es) | 2019-07-18 |
| JP2017055771A (ja) | 2017-03-23 |
| AU2011349049B2 (en) | 2016-08-11 |
| EA201390923A1 (ru) | 2013-12-30 |
| KR101941514B1 (ko) | 2019-01-23 |
| BR112013016235A2 (pt) | 2016-11-22 |
| AU2011349049A1 (en) | 2013-05-02 |
| US20130281677A1 (en) | 2013-10-24 |
| KR20140003494A (ko) | 2014-01-09 |
| EP2654790A1 (en) | 2013-10-30 |
| JP6147670B2 (ja) | 2017-06-14 |
| BR112013016235B1 (pt) | 2020-03-31 |
| ZA201305123B (en) | 2014-09-25 |
| MX2013007392A (es) | 2013-11-01 |
| US9505826B2 (en) | 2016-11-29 |
| IL227081B (en) | 2018-04-30 |
| EP2654790B1 (en) | 2019-02-06 |
| CA2824279A1 (en) | 2012-06-28 |
| JP2014503209A (ja) | 2014-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201305123B (en) | Modified antibody with improved half-life | |
| PL2581113T3 (pl) | Przeciwciało anty-tim-3 | |
| PL2530091T3 (pl) | Przeciwciało przeciwko dll3 | |
| ZA201209004B (en) | Anti-fgfr2 antibodies | |
| GB201000467D0 (en) | Antibodies | |
| PL2616489T3 (pl) | Przeciwciało anty-huTNFR1 | |
| IL221371A0 (en) | Anti-lrp6 antibodies | |
| IL224441B (en) | Antibodies with modified isoelectric points | |
| ZA201305323B (en) | Cea antibodies | |
| IL222222A0 (en) | Antibodies against csf-1r | |
| GB201103955D0 (en) | Antibodies | |
| GB201112056D0 (en) | Antibodies | |
| GB201020738D0 (en) | Antibodies | |
| PT2603528T (pt) | Anticorpos glicosilados em fab | |
| IL225667A0 (en) | A new antigen | |
| ZA201302459B (en) | Antibodies | |
| GB201002238D0 (en) | Antibodies | |
| LT2558499T (lt) | Antikūnai prieš vla-4 | |
| EP2714074A4 (en) | ANTIBODIES AGAINST EMR1 | |
| GB201007957D0 (en) | Antibody | |
| GB201017780D0 (en) | Antibody | |
| GB201020751D0 (en) | Antibodies | |
| GB201005062D0 (en) | Antibodies |